He showed a steady increase in breast cancer incidence that would soon reach the level of those observed in Western countries. Many factors appear to be related to this trend, including westernized foods, increasing fat intake, late marriage and no pregnancy. Regina G. Ziegler (National Cancer Institute, USA) showed in her paper 'Migration patterns, life style and breast cancer risk in Asian-American women' that, over several generations, AsianAmerican women could have a risk comparable to that of American whites. This study highlighted the impact of the exposure of Asian women to Western lifestyles on breast cancer risk and suggested new etiological aspects of the disease.
SESSION 2: PREVENTION, BASIC AND CLINICAL APPROACH
Minako Nagao overviewed experimental models of carcinogenesis under the title 'Induction and prevention of mammary cancers by food factors in the experimental animal system'. She reported that RCA-induced mammary carcinogenesis was suppressed by soy-hypocotyl, chlorophyllin, indole-3-carbinol, a naturally occurring phystochemical in cruciferous vegetables, and plant phenols. She suggested that modification of cooking conditions and addition of various anti-carcinogenic agents are a feasible way to delay onset of cancer in humans. Norman Wolmark (NSABP, USA) summarized a well-known trial in a presentation entitled 'The role of tamoxifen in breast cancer prevention: results of the NSABP breast cancer prevention trial (P-l)'. The conclusion was that tamoxifen decreased the incidence of invasive and non-invasive breast cancer, but at the price of an increased incidence of endometrial carcinoma and thrombotic disease. The benefits definitely outweighed the risks in certain patient categories.
SESSION 3: SCREENING PROGRAM
A screening program is crucial for the early detection of breast cancer and two speakers presented their recent data in this session. Laszlo Talbar (Falun Central Hospital, Sweden), gave a talk with the title 'Control of breast cancer through early detection: the natural history of breast cancer. What we have learned from screening'. He showed a significant reduction in breast cancer mortality achieved through mammographic screening in a Swedish trial. This was due to a significant decrease in the incidence of advanced-stage breast cancer. Noriaki Ohuchi presented a paper 'Perspective of mammographic screening of breast cancer in Japan' . He reported a Japanese case-control study of clinical breast examination which had failed to show its effecti veness as a screening method and stressed the importance of mammography. He described a current Japanese trial to evaluate mammographic screening and discussed a new direction in the organization of screening delivery.
SESSION 4: FAMILIAL BREAST CANCER AND GENE COUNSELING
In this session, recent progress in BRCAI and BRCA2 studies were reported. Piri L.Welcsh (University of Washington, USA) presented a paper entitled 'Genetic analysis of breast and ovarian cancer', in which she mentioned genomic-scale expression technologies and suggested that BRCA 1 target genes may be novel genes involved in either inherited or sporadic breast or ovarian cancer. Takashi Fukutomi (NCC, Japan) gave a paper entitled 'BRCAI and BRCA2 germline mutations in Japanese breast cancer families'. They examined germline mutations in Japanese breast cancer families and found that only 30% of the families had a mutation in one of the two genes, which was definitely low compared with those observed in Caucasian families. This suggested a different role of these genes in breast carcinogenesis between Japanese and Caucasian women.
SESSION 5: PATHOLOGY
This session had two speakers. D. Craig Allen (Graduate University of Utah, USA) presented 'Molecular pathology of human premalignant breast disease' and Hitoshi Tsuda presented 'A chromosomal rearrangement der(l6)t(l;16)/der(1;16) in breast cancer~histopathological and diagnostic implications'. The term 'molecular pathology' sounds unique, but it has begun to occupy an important area even in routine pathology, Allen mentioned that recent molecular studies using loss of heterozygosity have found clonal allelic imbalance at more than 100 genetic loci collectively involving nearly all chromosomes, suggesting that the evolution of premalignant breast lesions is very complex and involves a large number of activated oncogenes and mutated suppressor genes, most of which are still unknown. Tsuda reported that der( 16)t(1; 16)1der(l; 16) was detected in 77% of low-grade papillary carcinomas but not detected in papillomas. This rearrangement was detected in 33% of common breast cancers and correlated with better patient prognosis. Noguchi reported that K19RT-PCR assay was more sensitive than immunocytological methods in the detection of bone marrow micrometastases from breast cancer and suggested that the fonner could serve as a significant and independent risk factor for relapse.
SESSION 7: IMAGING DIAGNOSTICS AND SENTINEL NODE BIOPSY
Four papers were presented in this session, namely 'Diagnostic value ofcontrast-enhanced computed tomography for diagnosing the intraductal component and small invasive foci of breast cancer' by Sadako Akashi-Tanaka (NCC, Tokyo), 'Sentinel node evaluation for breast cancer' by David Krag (University of Vennont, USA), 'Japanese experience of sentinel node biopsy in 600 patients' by Masakuni Noguchi (Kanazawa University, Kanazawa) and 'Problems in sentinel node biopsy' by Tadashi Ikeda (Keio University, Tokyo). Akashi-Tanaka reported experience of contrast-enhanced helical CT in diagnosing intraductal components and small invasive foci of breast cancer. A high sensitivity as compared with conventional ultrasound or mammography was shown. Sentinel node biopsy is currently a hot subject in breast cancer surgery to achieve a minimally invasive lymphadenectomy. Technical aspects together with retrospective clinical data were discussed and the ongoing NCI-sponsored randomized trial which will recruite 4000 patients was presented.
SESSION 8: SURGERY AND POST-SURGICAL FOLLOW-UP
Three breast surgeons contributed to this session. Fujio Kasumi (Cancer Institute Hospital, Tokyo) presented 'Safe breast conservation without radiotherapy sustained by serial pathological examination of resected specimens'. He demonstrated by showing their experience of 1073 cases of breast conservative surgery that unnecessary post-operative irradiation could be avoided by examining the resected specimens serially. A problem with this method is that such meticulous pathological examination is possible only in selected institutions. Norman Wolmark of NSABP reported on 'The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ducal carcinoma in situ (DCIS): preliminary results of NSABP Protocol B-24'. He concluded that radiotherapy following lumpectomy for DCIS significantly reduced the subsequent incidence of invasive and non-invasive ipsilateral breast tumor recurrence and the addition of further reduces the cumulative 5 year incidence of subsequent breast cancer-related events. Prospective randomized trials will give answers to the questions of the· efficacy of high-dose chemotherapy in breast cancer. Yutaka Tokuda (Tokay University, Kanagawa) presented, in his paper entitled 'High-dose chemotherapy with autologous hematopoietic stem cell support in Japan', the 3-year progression-free survival rate of 14% of metastatic breast cancer patients who had shown a complete response (CR) or partial response (PR) to induction therapy and were treated with high-dose chemotherapy with autologous stem cell support. He suggested the necessity for developing more efficacious induction regimens to achieve higher CR rates.
SESSION 10: HORMONE RECEPTOR FUNCTION AND ENDOCRINE THERAPY
Suzanne A. W. Fuqua (University of Texas at San Antonio, USA) presented 'Molecular mechanisms of estrogen receptor action'. She reported recent data on the nuclear receptor co-regulator in transcriptional activation of estrogenic effects on breast cancer. She focused on the mechanisms for acquired resistance to tamoxifen, which is most frequently prescribed for breast cancer, and also d~scribed the mechanism of the pure anti-estrogen faslodex. Shigeaki Kato (University of Tokyo, Tokyo) presented 'Cross-talk of estrogen receptor function with growth factors' . He reported that MAP kinase activated by growth factors modulates the estrogen receptor molecule and modifies its function. This may be a novel cross-talk between estrogenic stimulation and the growth factor signaling pathway. He suggested that high levels of thymidine phosphorylase and low levels of vascular endothelial growth factor characterize patients with node-positive breast cancer treated with adjuvant CMF who had the highest likelihood of a favorable outcome. Ken Yamaguchi (NCC, Tokyo) presented 'Chemopreventive and anti-tumor effects of a synthetic progestational steroid, dienogest, in experimental mammary carcinoma models'. Based on a well designed in vivo model system, it was suggested that dienogest can be a potential candidate as an agent for hemoprevention and also endocrine therapy for breast cancer.
SESSION 11: BONE METASTASIS

SESSION 13: SUMMARY OF THE SYMPOSIUM
Kent Osborne (University of Texas at San Antonio) comprehensively summarized the symposium. DUling the past 30 years, various therapeutic and diagnostic agents have been developed and brought into breast cancer clinics. Owing to these developments, what was unknown or thought to be impossible has now become well known and possible. Continuing effort in both basic and clinical investigation into the 21 st century has cardinal importance. Throughout this symposium, several issues in breast cancer have become clear, mainly on the basis of mutual understanding of the Japanese delegates and guests from the overseas. The symposium was very useful and productive.
